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CORRESPONDENCE
Death from cumulative sodium stibogluconate
toxicity on Kala-Azar
Pentavalent antimonial compounds are the
most widely used drugs for the treatment of
leishmaniasis, but side-effects are frequent [1].
We report the case of a 4-year-old-male who was
diagnosed with visceral leishmaniasis after exam-
ination of a bone marrow biopsy. The patient was
started on 20 mg/kg intravenous sodium stiboglu-
conate daily (1200 mg/day) and 16 mg/kg oral
allopurinol daily (100 mg three times daily). This
regimen was supplemented with albumin and
blood. On day 3, he reported chest pain and
persistent cough, and the drugs were withdrawn.
Electrocardiography (ECG) was unremarkable at
that time. Three days after the treatment had been
discontinued, petechial rashes were seen on the
lower extremities. Sepsis and other causes of pete-
chial rash were ruled out. Three days after treat-
ment was discontinued, the patient was found
dead in bed. ECG showed ventricular fibrillation.
Sodium stibogluconate with a valency of 5þ and
meglumine antimonate are used in the treatment
of leishmaniasis [1]. Stibogluconate sodium (Pen-
tostam) is the term used in English-speaking coun-
tries, including the USA. Sodium stibogluconate
solution contains about 10% pentavalent antimony
(100 mg/mL) [1]. Side-effects include abdominal
pain, vomiting, nausea, fatigue, headache, increase
of liver enzymes, nephrotoxicity, arthralgia, fever,
rash, cough, pneumonia, pancytopenia and rever-
sible peripheral neuropathy. Recent studies sug-
gest that elevations of amylase and lipase are
common, and that a subset of patients suffer clini-
cally significant pancreatitis. Nonetheless, these
side-effects rarely lead to discontinuation of the
drug [2–4].
Dose-related changes in ECG can also be seen.
Nevertheless, serious side-effects, such as atrial
and ventricular arrhythmia, atrial fibrillation, ven-
tricular tachycardia, ventricular fibrillation, and
torsade de pointes, are rare. Torsade de pointes
induced by pentavalent antimony, followed by
sudden death, has been observed [3–5]. Arrhyth-
mias and sudden death have been reported with
doses greater than 20 mg/kg body weight/day [1].
Administration of the drug at normal doses rarely
results in the death of patients. It should be kept in
mind that pentavalent antimony is contraindicated
in patients with myocarditis, hepatitis and pan-
creatitis [6,7].
Even the normal dose of sodium stibogluconate
can lead to both cardiotoxicity and hematotoxicity,
because of its cumulative effects. These side-effects
may occur even after the drug is withdrawn, as in
our case. We therefore suggest that patients with
leishmaniasis who are being treated with anti-
mony compounds be observed cautiously for signs
of cardiologic and hematologic changes.
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